13 years ago

Glythera Secures £2 Million in Funding for Protein/Peptide Therapeutics

  • Glythera, a Newcastle-upon-Tyne based biopharmaceutical company specializing in protein/peptide functionalizazion and glycosylation, has secured £2 million in funding over three years

  • The initial £600,000 investment was split equally between IP Group and its managed fund, the Finance for Business North East Technology Fund

  • The company, a spin-out from the University of Bath, recently established commercial operations at Newcastle’s INEX incubator facility and appointed Dr David Simpson as Chief Operating Officer

  • Glythera's core technologies – Permalink and Permacarb – enable the selective and stable functionalization and glycosylation of biopharmaceuticals for improved stability, bioavailability, and efficacy.

      • ProblemHealthcare

      "Developing new and effective protein and peptide-based drugs is expensive and time-consuming. Current methods often struggle with stability, bioavailability and efficacy, leading to inefficient treatments and high costs for patients."

      Solution

      "Glythera offers a revolutionary approach to protein/peptide functionalization and glycosylation using proprietary technologies like Permalink and Permacarb. These technologies improve stability, bioavailability and efficacy of protein/peptide therapeutics, making them more effective and cost-effective for patients."

      Covered on